Healthcare of Ontario Pension Plan Trust Fund Makes New Investment in Haemonetics Corporation $HAE

Healthcare of Ontario Pension Plan Trust Fund bought a new position in Haemonetics Corporation (NYSE:HAE) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 114,277 shares of the medical instruments supplier’s stock, valued at approximately $6,441,000.

Several other large investors have also recently modified their holdings of the business. Kemnay Advisory Services Inc. bought a new stake in shares of Haemonetics in the fourth quarter valued at approximately $26,000. Leonteq Securities AG bought a new position in Haemonetics in the 4th quarter worth approximately $30,000. EverSource Wealth Advisors LLC grew its stake in Haemonetics by 2,640.0% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock valued at $31,000 after buying an additional 396 shares in the last quarter. Kestra Advisory Services LLC bought a new stake in Haemonetics during the 4th quarter valued at $34,000. Finally, Bayforest Capital Ltd bought a new stake in Haemonetics during the 4th quarter valued at $40,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Haemonetics Price Performance

HAE stock opened at $85.63 on Thursday. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.95 and a quick ratio of 1.87. Haemonetics Corporation has a one year low of $47.31 and a one year high of $87.32. The stock has a market cap of $3.89 billion, a PE ratio of 42.39, a P/E/G ratio of 1.66 and a beta of 0.52. The firm has a 50 day simple moving average of $74.25 and a two-hundred day simple moving average of $66.05.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.01. The firm had revenue of $346.35 million for the quarter, compared to analysts’ expectations of $336.83 million. Haemonetics had a net margin of 7.29% and a return on equity of 27.30%. The business’s quarterly revenue was up 4.8% on a year-over-year basis. During the same quarter last year, the company posted $1.24 EPS. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. On average, analysts predict that Haemonetics Corporation will post 5.21 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on HAE. BTIG Research reaffirmed a “buy” rating and issued a $84.00 price target on shares of Haemonetics in a report on Friday, June 26th. Wall Street Zen upgraded Haemonetics from a “hold” rating to a “buy” rating in a research note on Saturday, May 23rd. Bank of America raised Haemonetics from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $72.00 to $80.00 in a report on Friday, May 22nd. JPMorgan Chase & Co. reduced their target price on Haemonetics from $74.00 to $62.00 and set a “neutral” rating for the company in a report on Friday, May 8th. Finally, Barrington Research decreased their price target on Haemonetics from $94.00 to $89.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 12th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Haemonetics has an average rating of “Moderate Buy” and a consensus target price of $78.89.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.